Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 1(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01271348Phase 1Completed

Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise

Role: lead

NCT01415050Phase 2Completed

Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women

Role: lead

NCT01301677Phase 1Completed

Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone

Role: lead

NCT01055249Phase 1Completed

UVB Model Validation Study

Role: lead

NCT01020279Phase 1Completed

Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise

Role: lead

All 5 trials loaded